EGFR and non-small cell lung carcinoma: Recently, various clinical studies have reported that the status of EGFR gene mutations at exons 18–2 l in the tyrosine kinase coding domain are correlated with the therapeutic response of both gefitinib or erlotinib for NSCLC patients1,2.